

DATE: October 21, 2008

FROM: Dianne Murphy, MD, FAAP
Director, Office of Pediatric Therapeutics
Office of the Commissioner
U.S. Food and Drug Administration

SUBJECT: Overview of the November 18, 2008, Meeting of the Pediatric Advisory Committee

TO: Members of the Pediatric Advisory Committee and invited Expert Consultants

Thank you for participating in the upcoming Pediatric Advisory Committee (PAC) meeting on November 18, 2008. The agenda for this meeting is included in this mailing. We sincerely appreciate your time, insights, and expert advice provided during the PAC meeting.

On November 18th, the PAC will meet in a public session, to discuss adverse event reports for drugs granted pediatric exclusivity, as originally mandated by Section 17 of the Best Pharmaceuticals for Children Act (BPCA). Title IV Section 505B(i) and Title V Section 505A(l) of FDAAA, passed in September of 2007, extended and expanded the safety review activities of the PAC.

Eleven (11) drug safety reviews will be presented for your assessment; nine new products and two products recommended for follow-up at previous PACs. Please note, we are initiating a new process at this PAC meeting, whereby, all products with few or no pediatric adverse events will be presented in an abbreviated process. The oral presentation will include a single-slide listing only the name of the products identified for an abbreviated process, rather than individual presentations for each product. FDAAA almost doubled the safety review activities of the PAC. We continue to explore ways to develop more efficient approaches while ensuring a full and robust safety review process.

- Seven products will have standard Adverse Event presentations: **Risperdal (risperidone), Zyprexa (olanzapine), Levaquin (levofloxacin), Lamictal (lamotrigine), Ambien (zolpidem), Lamisil (terbinafine), and Aldara (imiquimod).**
- Two products have been identified for the abbreviated process: **Betoptic S (betaxolol) and Timolol GFS (timolol).**
- Two products will have follow-up information provided: **Sandostatin (octreotide) and Zyvox (linezolid).**
 - At the April 2007 PAC, the Committee recommended that the FDA continue monitoring Sandostatin (octreotide) and provide another review at a future PAC. The expanded review for Sandostatin (octreotide) will include: (1) an introduction on octreotide use in infants by Rama Bhat, M.D., Professor of Pediatrics and Director of Neonatology, at the University of Illinois-Chicago, (2) a safety

presentation by the FDA Pediatric and Maternal Health Staff Medical Officer, and (3) a presentation from a representative from Novartis.

- At the November 2006 PAC, the committee requested a follow-up report on Zyvox (linezolid) upon completion of the pending review of cardiac events for all age populations. This report is being provided in the background materials as a document only, and there will be no presentation at the PAC. There will be an opportunity to ask questions concerning the review.

After the safety review portion of the meeting, there will be an update on the Pediatric Ethic Subcommittee activities, including an update on the Subcommittee meeting held June 9-10, 2008. After the Pediatric Ethics update, the PAC will be adjourned.

The background package for this meeting includes the following additional documents:

Adverse Event Related Materials

- Adverse Event Safety Reviews for 11 products
- OPT Integrated Safety Summary and OSE addendum for Ambien (zolpidem)
- Zyvox (linezolid) memo
- Medication Error report for Lamisil (terbinafine)

Use Reviews

- Drug Use Reviews for 10 drugs

Additional documents

- The Clinical and Clinical Pharmacology summary reviews for 8 products (Betoptic S (betaxolol) and Timolol GFS (timolol) have only Clinical summaries)
- Full Clinical, Pharmacology, and Statistical review for 1 product labeled since passage of FDAAA
- Selected materials from the past PAC are provided for 2 follow-up products, Zyvox (linezolid) and Sandostatin (octreotide), and a recent article on octreotide use in infants
- Information for Healthcare Professionals on fluoroquinolones including Levaquin (levofloxacin) and Suicidality and Antiepileptic Drugs including Lamictal (lamotrigine)
- Labeling for each product

The FDA relies heavily on the expert knowledge, judgment, experience, and wisdom of the members of advisory committees to provide us with feedback and advice on how best to promote and protect the public health of the United States. We thank you for your time and effort, and we look forward to seeing you.